125I radioactive seed localization for non-palpable lesions in breast cancer

Sánchez, R. Sánchez; Jiménez, Ángela Conchillo; Aguirre, A.C. Rebollo; Arnau, Inmaculada Mendoza; Beltrán, Salomón Menjón; Alcaide, M.E. Vergara; Ceballos, J.L. Osorio; Elvira, J.M. Llamas

doi:10.1016/j.remnie.2019.07.001

“…(125)I radioactive particles are implanted within the range of radiation therapy, and the dose of radiation dose decreases with the increase of distance. Therefore, (125)I particle implantation can produce a high dose at the site, while the radiation dose of surrounding normal tissues is low, with highly conformal radiation [ 13 – 15 ]. Zhao et al found that (125)I seed implantation based on CT-guided 3D template-assisted technique can effectively alleviate the tumor and improve the survival rate in patients with refractory malignant tumors [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer

Jiang

¹

,

Pang

²

,

Xia

³

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To investigate the clinical value of lentinan combined with (125)I brachytherapy in the treatment of recurrent ovarian cancer. Methods. A total of 160 patients with recurrent ovarian cancer admitted at Jiaozhou Central Hospital from June 2009 to October 2015 were enrolled in this study and randomly divided into observation group (80 cases) and control group (80 cases). The control group received chemotherapy. Observation group (80 cases) was treated with lentinan combined with (125)I brachytherapy on the basis of control group, and the efficacy, adverse reactions, and Karnofsky Performance Scale (KPS) and quality of life scale (QOL) scores of the two groups were analyzed and compared. Results. After treatment, the levels of CA125, CA199, and CA724 in the 2 groups were markedly lower than those before treatment, and the observation group was lower than the control group ( P < 0.05 ). After treatment, the proportion of CD4+/CD8+ cells and helper T cells and NK cells in the control group remarkably depleted, while the proportion of CD4+/CD8+ cells, NK cells, and B cells in the observation group increased significantly compared to that before treatment, and the level of IgA, IgG, and IgM in the control group decreased, while that in the observation group showed no conspicuous difference compared with that before chemotherapy ( P > 0.05 ). The effective rate of observation group (85%) was higher than that of control group (75%) ( P < 0.05 ). The overall survival of patients in the control group was (16.2 ± 2.04) months and that of the observation group was (24.8 ± 1.8) months. KPS and QOL scores in both groups were enormously higher than those before treatment, and the observation group was higher than the control group ( P < 0.05 ). The incidence of hemoglobin reduction, leukopenia, aglobulia, granulocytopenia, nausea and vomiting, hepatorenal toxicity, and neurovirulence in the observation group was significantly lower than that in the control group. Conclusion. Lentinan combined with (125)I brachytherapy is effective in treating recurrent ovarian cancer, with mild adverse reactions and good tolerance.

show abstract

“…Reoperation rates were reported by 27 studies [29,35,[38][39][40][41][42][44][45][46][47][48][49][50][51][52][53][54][55][56][57][60][61][62][63][64][65][66][67]69,70], with a relevant heterogeneity (I 2 = 61%). The reoperation risk after conservative surgery with RSL was lower than with WGL (RR = 0.71, 95% CI = 0.61-0.84; 13884 patients; 27 studies; see Figure 8).…”

Section: Reoperationmentioning

confidence: 99%

“…The complications rates related to marker implantation were reported by 25 studies [30,[33][34][35][41][42][43][44][45][46][47][48][49][50][51][52]55,57,60,61,64,[67][68][69][70], with a relevant heterogeneity (I 2 = 57%). The complications risk in conservative surgery with WGL was lower than with RSL, but this value was not statistically relevant (RR = 1.12, 95% CI = 0.66-1.78; 8672 patients; 25 studies; see Figure 11).…”

Section: Complicationsmentioning

confidence: 99%

“…Post-operative complication rates were reported by 13 studies [29,31,32,41,42,44,48,51,60,61,[64][65][66], without heterogeneity (I 2 = 0%). The post-operative complications risk after conservative surgery with WGL was lower than with RSL, but this value was not statistically relevant (RR = 1.17, 95% CI = 0.90-1.52; 5525 patients; 13 studies; see Figure 12).…”

Section: Complicationsmentioning

confidence: 99%

See 1 more Smart Citation

Radioactive Seed Localization for Nonpalpable Breast Lesions: Systematic Review and Meta-Analysis

Ferreira,

de Souza,

Pozzo

et al. 2024

View full text Add to dashboard Cite

Background: This study is a systematic review with meta-analysis comparing radioactive seed localization (RSL) versus radio-guided occult lesion localization (ROLL) and wire-guided localization (WGL) for patients with impalpable breast cancer undergoing breast-conserving surgery and evaluating efficacy, safety, and logistical outcomes. The protocol is registered in PROSPERO with the number CRD42022299726. Methods: A search was conducted in the Embase, Lilacs, Pubmed, Scielo, Web of Science, and clinicaltrials.gov databases, in addition to a manual search in the reference list of relevant articles, for randomized clinical trials and cohort studies. Studies selected were submitted to their own data extraction forms and risk of bias analysis according to the ROB 2 and ROBINS 1 tools. A meta-analysis was performed, considering the random effect model, calculating the relative risk or the mean difference for dichotomous or continuous data, respectively. The quality of the evidence generated was analyzed by outcome according to the GRADE tool. Overall, 46 articles met the inclusion criteria and were included in this systematic review; of these, 4 studies compared RSL and ROLL with a population of 1550 women, and 43 compared RSL and WGL with a population of 19,820 women. Results: The results showed that RSL is a superior method to WGL in terms of surgical efficiency in the impalpable breast lesions’ intraoperative localization, and it is at least equivalent to ROLL. Regarding security, RSL obtained results equivalent to the already established technique, the WGL. In addition to presenting promising results, RSL has been proven to be superior to WGL and ROLL technologies.

show abstract

“…At present, 125 I particle has a good effect in the treatment of prostate cancer, lung cancer, pancreatic cancer, and other solid tumors [ 5 , 6 ]. Some scholars found that 125 I particle therapy could alleviate the clinical symptoms related to lymph node metastasis in patients with refractory differentiated TC with effective and safe local control effect in tumor for short term [ 7 ]. However, there are few studies on the effects of different 125 I particle treatment dose parameters on the patients.…”

Section: Introductionmentioning

confidence: 99%

Analysis of the Influencing Factors of Tumor Volume, Body Immunity, and Poor Prognosis after 125I Particle Therapy for Differentiated Thyroid Cancer

Tan

¹

,

Chen

²

,

Wang

³

et al. 2023

Mediators of Inflammation

0

View full text Add to dashboard Cite

Objective. To analyze the influencing factors of tumor volume, body immunity, and poor prognosis after 125I particle therapy for differentiated thyroid cancer. Methods. A total of 104 patients with differentiated TC who were treated with 125I particles during January 2020 to January 2021 was picked. These subjects were graded as low-dose group (80Gy-110Gy) and high-dose group (110Gy-140Gy) according to the minimum dose received by 90% of the target volume (D90) after surgery. The tumor volume before and after treatment was compared, and fasting venous blood was collected before and after treatment. The content of thyroglobulin (Tg) was detected by electrochemiluminescence immunoassay. The levels of absolute lymphocyte count (ALC), lymphocytes, neutrophils, and monocytes were detected on automatic blood cell analyzer. The lymphocyte to monocyte ratio (LMR), neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ration (PLR) were calculated. The changes in the condition of patients were closely observed, and the occurrence of adverse reactions in the two groups were compared. The risk factors influencing the efficacy of 125I particle therapy for differentiated TC were analyzed through multivariate logistic regression analysis. Results. The total effective rate of patients in the low- and high-dose groups was 78.85% and 82.69%, respectively ( P > 0.05 ). Compared with the pretreatment period, the tumor volume and Tg level in both groups were much lower ( P < 0.05 ), and the differences in tumor volume and Tg level had no statistically significant difference between the two groups before and after treatment ( P > 0.05 ). At 1 week of the treatment, the total incidence of adverse reactions such as nausea, radiation gastritis, radiation parotitis, and neck discomfort was obviously higher in the high-dose group than in the low-dose group ( P < 0.05 ). At 1 month of treatment, the incidence of adverse reactions such as nausea was markedly higher in the high-dose group than in the low-dose group ( P < 0.05 ). After treatment, serum NLR and PLR contents were memorably elevated and LMR level was sharply decreased in both groups, and serum NLR and PLR contents were higher and LMR content was lower in the high-dose group than in the low-dose group ( P < 0.05 ). Multivariate logistic regression analysis showed that the pathological type of follicular adenocarcinoma, tumor size ≥ 2 cm, clinical stage of III~IV, distant metastasis, and high TSH level before 125I particle treatment were all risk factors related to the efficacy of 125I particle treatment of TC ( P < 0.05 ). Conclusion. The efficacy of low-dose and high-dose 125I particles in the treatment of differentiated thyroid cancer is comparable, among which low-dose 125I particles have fewer adverse effects and have less impact on the immunity of the body, which is well tolerated by patients and can be widely used in clinical practice. In addition, the pathological type of follicular adenocarcinoma, tumor size ≥ 2 cm, clinical stage III~IV, distant metastasis, and high TSH level before 125I particle treatment are all risk factors that affect the poor effect of 125I particles on thyroid cancer treatment, and early monitoring of the above index changes can help evaluate the prognosis.

show abstract

125I radioactive seed localization for non-palpable lesions in breast cancer

Cited by 4 publications

References 19 publications

Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer

Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer

Radioactive Seed Localization for Nonpalpable Breast Lesions: Systematic Review and Meta-Analysis

Analysis of the Influencing Factors of Tumor Volume, Body Immunity, and Poor Prognosis after 125I Particle Therapy for Differentiated Thyroid Cancer

Contact Info

Product

Resources

About